View Older Stories View More Recent Stories
-
Be Biopharma to Present at the 35th Annual Piper Sandler Healthcare Conference
-
Jnana Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference
-
Form SC 13D/A Eliem Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
NTx Raises $47.5M in Series B Funding to Advance Next Generation Biomanufacturing
-
Form 13F-HR/A RA CAPITAL MANAGEMENT, For: Sep 30
-
MBX Biosciences to Participate in Piper Sandler 35th Annual Healthcare Conference
-
LENZ Therapeutics and Graphite Bio (GRPH) Announce Merger Agreement
-
LENZ Therapeutics and Graphite Bio Announce Merger Agreement
-
Form SC 13G/A Design Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form 13F-HR RA CAPITAL MANAGEMENT, For: Sep 30
-
Forward Therapeutics Announces $50 Million Series A Financing to Advance Next-Generation Small Molecule Immune Therapies
-
Blackbird Labs, a Next-Generation Life Sciences Accelerator, Launches with $100 Million and Foundational Collaboration with Johns Hopkins University
-
Form SC 13G Harpoon Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
T-knife Therapeutics Announces the Appointment of Simone Silva Steiner, Ph.D., as Chief Technical Operations Officer
-
Be Biopharma to Present New Preclinical Study Demonstrating Its Precision-Engineered B Cell Medicine Produces Active and Sustained Levels of Factor IX
-
MBX Biosciences Announces Appointment of Michelle Graham as Chief Human Resources Officer
-
Be Biopharma Presents Preclinical Data Demonstrating Ex-Vivo Engineered B Cell Medicines Produce Highly Active and Sustained Levels of Antitumor Biologics
-
MBX Biosciences to Participate in Stifel 2023 Healthcare Conference
-
Form SC 13G MACROGENICS INC Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Be Biopharma Presents Data from Preclinical Studies Showing Engineered B Cells Produce Highly Active Therapeutic Proteins and Demonstrate Durable Engraftment Without Pre-Conditioning
-
Aiolos Bio Launches with $245 Million Series A Investment to Advance Development of Novel, Phase 2-Ready TSLP Antibody
-
Rampart Bioscience Announces $85M Series A Financing to Develop Novel DNA-Based Medicines with Veteran Team
-
Harpoon Therapeutics Inc. (HARP) Announces Up to $150 Million Private Placement
-
Harpoon Therapeutics Announces Up to $150 Million Private Placement
-
Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million
-
Adela Presents Data Demonstrating Strong Prognostic Prediction Capabilities in Head and Neck Cancer and Renal Cell Carcinoma at the ESMO 2023 Congress
-
Ventricle Health secures $8M in seed financing led by RA Capital Management, along with Waterline Ventures and others to accelerate national delivery of its value-based home care model for heart failu
-
Amplifier Therapeutics, a Cambrian Bio pipeline company, doses first patients in Phase 1B clinical trial and closes new financing from Future Ventures and RA Capital Management
-
MBX Biosciences Presents Positive Results from Phase 1 Study of MBX 2109 in Late-Breaking Oral Presentation at the American Society for Bone and Mineral Research Annual Meeting
-
NVCA Updates Industry Standard Model Legal Documents to Empower Venture Community
-
Be Biopharma to Present at 2023 Cell & Gene Meeting on the Mesa
-
Commons Clinic Announces $19.5M Series A Financing to Unseat Specialty Care Incumbents With its New Model for Spinal Care, Orthopedics, and Pain Management
-
MBX Biosciences Doses First Participant in Phase 1/2 Clinical Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia
-
Form SC 13G SOLENO THERAPEUTICS INC Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Jnana Therapeutics to Participate in Upcoming Investor Conferences
-
SAB Biotherapeutics Approves Appointment of Andrew Moin to Board of Directors
-
Orchard Therapeutics (ORTX) Acquired by Kyowa Kirin for $16/sh Cash plus $1 CVR
-
MBX Biosciences to Showcase Results from Phase 1 Study of MBX 2109 in Late-Breaking Oral Presentation at the American Society for Bone and Mineral Research Annual Meeting
-
SAB Biotherapeutics (SABS) Announces Private Placement of up to $130 Million
-
SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes
-
Form SC 13G CHIMERIX INC Filed by: RA CAPITAL MANAGEMENT, L.P.
-
T-knife Therapeutics Announces Four Presentations at the Upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting
-
Form SC 13D/A ARS Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Adela Announces $48 Million in Financing and Leadership Addition to Advance Tissue-Agnostic Minimal Residual Disease (MRD) Monitoring Product Portfolio Based on Genome-Wide Methylome Approach
-
Form SC 13G CymaBay Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13D/A Cytek Biosciences, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Hyku Biosciences Launches With $56M to Advance its Covalent Medicines Platform to Expand the Boundaries of Drug Discovery
-
EntityRisk Launches PROVEN™ Platform
-
MBX Biosciences Announces Positive Phase 1 Multiple Ascending Dose Data for MBX 2109, a Long-Acting Parathyroid Hormone Peptide Prodrug, in Healthy Adults
-
Mariana Oncology Announces $175 Million Series B Financing
